Next Phase Newsletter

A global medical technology company based in London, UK focuses on cardiovascular and neuromodulation technologies. The firm typically invests early on in the development (series A or B) stage. The firm seeks to invest in the range of $1M-$15M per company, though would pursue larger ($100M and up) deals if there were a strong rationale that would make the company an ideal, revenue-generating fit to the portfolio. The firm currently manages a growing fund, and seeks to make 1-2 larger deals and 3-4 smaller ones within the next year. The firm seeks investments globally, and has a specific focus on USA and European-based companies.

Sectors & Subsectors of Interest: 

The firm focuses on medical devices in the cardiovascular space (cardiovascular disease and associated comorbidity such as sleep apnea, etc.), specifically in technology for invasive procedures and neuromodulation areas such as stimulation for heart failure. In the cardiovascular space, the firm has interest in cardiac surgery technology, such as minimally invasive valves, tissue valves, mechanical heart valves, open-heart valves, blood circulation and transfusion technology, and blood management systems, among others. The firm is also interested in cardiac rhythmic management, such as remote monitoring technology, electro and neurostimulation, software technology, and pacemakers.

The firm will look at companies in the clinical, close to end of development stage that may be in its final round of fundraising for clinical trials. The firm is not currently focused on therapeutics or lab equipment technology, though may be open to those used to assist procedures in the cardiovascular/neurostimulation space. The firm looks at both PMA and 510K devices, as it traditionally invests in PMA devices, and is now gaining an increasing interest in 510K devices.

The firm prefers experienced management teams, and may take a board or observer seat after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A specialty pharmaceutical company headquartered in Japan focuses on pharmaceuticals, medical devices, and agro-veterinary products. The firm has strong experience in developing and commercializing novel pharmaceuticals and medical devices in the fields of orthopedics, dermatology and surgery. The firm is currently seeking R&D collaboration and marketing alliance opportunities across Japan, Europe, US, Asia and the rest of the world.

Currently the firm is looking for innovative therapeutic products in the following areas: orthopedics with a focus on inflammation and pain, including RA/OA/arthritis pain/low-back pain; dermatology including dermatitis/acne/psoriasis; and mycology including topical and systemic treatments. The firm is also interested in peri-surgical medical devices as well as ophthalmology and niche market products.

The firm seeks to partner with publicly and privately held life science companies with experienced management teams and innovative technologies in the abovementioned areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm backed by a single HNW individual is based in California with additional offices in Israel.  The firm focuses on seed and series A investments and usually makes investments in the range of $250K-$5M. Investments may be in the form of convertible notes or straight equity, depending on the company and terms of the deal.  The firm’s nimble structure allows some flexibility in terms of capital structure, investment size etc. The firm will lead rounds as well as syndicate with other investors, and has as large network and access to additional capital.

In terms of the life sciences, the firm is interested in technology at the intersection of data and healthcare with a particular interest in algorithms for increasing efficiency/efficacy of early-stage drug discovery. The firm is also interested in medical devices and diagnostic technologies.

The firm is open to companies globally, but prefers to invest in companies located in or close to the Bay Area or Israel. The firm will work with all types of entrepreneurs, but would like to see meaningful references for novice entrepreneurs. A board seat is not required, but may be sought depending on the company and investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A seed fund founded by a China-based investment firm supports early stage companies and helps startups from the US and Europe expand successfully into the China market.  The fund is an active early stage medtech and biotech investor. The firm supports companies throughout the development process and typically invests up to $500,000 per company. The seed fund has particular success in fostering joint development initiatives between U.S. and China-based companies, and invests in companies based in the U.S., China and Europe.

The fund invests in early stage therapeutics, medical devices, diagnostics, and healthcare services and IT that may still need FDA approval and have a fast-track clinical development platform approved by the China SFDA. The firm is particularly interested in companies that have clinical development plans and interest in China. The fund is also open to lab equipment and drug development enabling technology.

The fund supports companies who have an international business model with desire to expand into the US, China, and/or Europe.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment firm based in Taiwan is interested in the life sciences and will target new investments from a new USD 100 million fund. The fund’s target investment size is USD 3-5 million per company and USD 1-1.5 million for early stage companies. Capital allocation per company will not exceed 10% of the fund. The firm seeks companies in the Asia-Pacific region and in the US. The firm is actively seeking new investment opportunities.

In the life sciences, the firm is interested in therapeutics, medical devices, and diagnostics. For therapeutics, the firm will consider a broad range of modalities including small molecules and biologics with an emphasis on stem cell, immunotherapy, and CNS therapies. The firm is opportunistic in terms of indications. For companies in Asia, the firm is agnostic to the phase of development. For overseas deals, the firm is currently looking for preclinical to phase 2 assets. The firm prefers candidates with in-human data and are conducting clinical trials in the US, while this is not a requirement.

For devices, the firm considers minimally invasive class III devices in the cardiovascular and cancer space that have prototype and have obtained proof-of concept. For diagnostics, the firm is interested in genomics and big data analytics. Recently there is an interest in the cosmetics and supplements area, and the firm is seeking acquisition opportunities to commercialize products through distribution channels within its network.

The firm only invests in private companies and looks to hold less than 15 percent of total shares of the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Venture Capital firm founded in 2000 and based in the US Southeast has $250 million in assets under management. The firm recently had a first close on its new fund, with up to 20% of the committed capital going to seed and early stage companies and projects. The firm typically invests between $2 and $4 million initially and $6M to $10M over the lifetime of the investment. Investments are generally in the form of milestone based equity tranches, however the firm also has experience in working with convertible notes. The firm is looking to make 4-6 allocation in the next 6-9 months throughout the United States, focused on companies in the Southeast.

The firm is currently looking for early stage companies in the Therapeutics, Diagnostics, Medical Technology and HealthCare IT spaces. In the Therapeutics space the firm is opportunistic in terms of subsector but is most interested in indications of Ophthalmology, Cardiovascular, Pulmonary, Anti-Infectives, Metabolic Disorders, Renal Diseases, Oncology, Immunology, Dermatology, and Orphan Diseases. For companies developing therapeutics the firm is looking for companies primarily with a lead product in preclinical trials although they will consider companies with products having recently entered Phase I. The firm also has generally stayed away from and is not currently seeking companies working in Wound Care. In the Medical Technology space the firm strongly prefers that the company have at least have an early prototype of their product and the firm is opportunistic in terms of medical device subsector. The firm looks for companies in the healthcare IT space to be revenue generating.

For Healthcare IT investments, the firm looks only at post-revenue companies; however, for drug and device deals, the firm only invests in pre-revenue companies, often working with spinouts directly from universities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An East Coast-based hedge fund is seeking to make 3-4 new equity investments into companies at the Series C stage or later, with commercial sales (at least Series C) in North America, or Europe with plans to enter the U.S. market. The firm is open to companies headquartered anywhere, but requires that products are approved and sold in Europe and/or the US. For companies with enterprise values of $20m – $200m, the firm commits $5m – $20m and is willing to lead rounds or join syndicates as long as the investment gives a meaningful stake in the company for the purposes of being able to add value.

The firm is interested in commercial-stage medical devices and diagnostics, and focuses on products that help fill a large unmet need and have a strong health economic value proposition. The firm prefers the technology to be commercial-stage or at least past FDA-approval and close to generating revenue. Within medical devices, the firm prefers devices with strong IP protection, generally with PMA or 510(k) approval. Within diagnostics, the firm is very opportunistic though their recent experience has focused on cancer genomic testing. The firm is open to all indication areas but historically has focused on cardiovascular, oncology and minimally invasive surgery.

The firm looks for seasoned management teams that have relevant experience in the sector the company is involved in. The firm likes to see this across the C-suite, particularly in the CEO and sales and marketing leadership. The firm takes a board seat when making investments and looks to add value through active involvement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com